Article
[Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir combined with ribavirin in Asian adult patients with chronic HCV genotype 1b infection and compensated cirrhosis].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 20 May 2018
Wei L, Wang G Q, Sarah J, Cheng Q, Xie M R, Wang M, Xu Z P, Duan J L, Hou M X, Zhang Y X, Zhang G, Tang W, Zhao S M, Lin Z S, Jia J J, Niu Z L, Gao H, Yuan M H, Lin X M, Zhou J D, Luo Yan, Linda Fredrick, Niloufar Mobashery, Wang Ye, Jia Jidong
Abstract excerpt
Objective: To evaluate the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) 25/150/100 mg once daily and dasabuvir (DSV) 250 mg twice daily combined with ribavirin in adult patients of Mainland China with chronic HCV genotype 1b infection and compensated cirrhosis. Methods: An open-label, multicenter, phase 3 clinical trial study was conducted in mainland China, Taiwan, and South Korea. Adult...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.